Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Express Scripts
Federal Trade Commission
Citi
Julphar
Merck
Colorcon
Moodys
Harvard Business School

Generated: October 20, 2017

DrugPatentWatch Database Preview

EVOXAC Drug Profile

« Back to Dashboard

Which patents cover Evoxac, and when can generic versions of Evoxac launch?

Evoxac is a drug marketed by Daiichi Sankyo Inc and is included in one NDA.

The generic ingredient in EVOXAC is cevimeline hydrochloride. There are four drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cevimeline hydrochloride profile page.

Summary for Tradename: EVOXAC

US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list27
Patent Applications: see list577
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EVOXAC at DailyMed

Pharmacology for Tradename: EVOXAC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EVOXAC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000► Subscribe► Subscribe
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000► Subscribe► Subscribe
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for EVOXAC

Drugname Dosage Strength RLD Submissiondate
cevimeline hydrochlorideCapsules30 mgEvoxac2/27/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Cantor Fitzgerald
Covington
McKesson
McKinsey
Fish and Richardson
AstraZeneca
Dow
QuintilesIMS
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot